NanoSphere Health Sciences Inc.
NSHSF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.01 | 0.01 | -0.00 |
| FCF Yield | -32.19% | 57.59% | 12.53% | -5.14% |
| EV / EBITDA | -29.88 | -5.36 | -7.74 | 0.78 |
| Quality | ||||
| ROIC | 3.91% | 2.67% | 3.27% | 3.73% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 7.01 | -1.60 | -0.53 | -0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -394.13% | -56.34% | 448.02% | 68.75% |
| Safety | ||||
| Net Debt / EBITDA | -5.17 | -2.85 | -0.58 | 0.07 |
| Interest Coverage | -46.40 | -203.62 | -56.84 | -58.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |